Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized treatment in the eradication therapy for Helicobacter pylori.

International journal of molecular medicine - 1 Feb 2011

Jinda Sayaka, Nakatani Kaname, Nishioka Junji, Yasuda Kazunari, Soya Yoshihiro, Hayashi Amiko, Wada Hideo, Nobori Tsutomu

Abstract excerpt

Helicobacter pylori (HP) is known to be a causative bacterium of gastritis and peptic ulcers. The combination treatment consisting of a proton pump inhibitor (PPI), amoxicillin and clarithromycin (CAM) is widely used in eradication therapy, but the eradication fails in some patients. The main causes are CAM resistance of HP and individual variability in PPI metabolism related to the activity of the cytochrome...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Clarithromycin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Drug Resistance, Bacterial

Share to Gastric Mucosa

Share to Helicobacter Infections

Share to Helicobacter pylori

Share to Precision Medicine

Source

Identifiers

PMID: 21132257
DOI: 10.3892/ijmm.2010.569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized treatment in the eradication therapy for Helicobacter pylori.PMID 21132257Read ↗

Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.Semantic proximity Read ↗

Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of Gastritis.Semantic proximity Read ↗

Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature ReviewSemantic proximity Read ↗

Analysis of drug resistance in Helicobacter pylori by complete genome sequencing in Bama County, Guangxi, ChinaSemantic proximity Read ↗

Application of Visual Gene Clip-Based Tailored Therapy for the Eradication of Helicobacter pylori.Semantic proximity Read ↗

Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach.Semantic proximity Read ↗

Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.Semantic proximity Read ↗

Assessment of Helicobacter pylori positive infected patients according to Clarithromycin resistant 23S rRNA, rpl22 associated mutations and cyp2c19*1, *2, *3 genes pattern in the Early stage of GastritisSemantic proximity Read ↗

Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.Semantic proximity Read ↗

Analysis of Drug Resistance in Helicobacter Pylori by Complete Genome Sequencing in Bama County, Guangxi, ChinaSemantic proximity Read ↗

Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.Semantic proximity Read ↗

Pharmacogenomics-based treatment of Helicobacter pylori infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.